Comparative Pharmacology
Head-to-head clinical analysis: NESINA versus SAXAGLIPTIN METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NESINA versus SAXAGLIPTIN METFORMIN HYDROCHLORIDE.
NESINA vs SAXAGLIPTIN;METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of dipeptidyl peptidase-4 (DPP-4), preventing inactivation of incretin hormones (GLP-1, GIP), thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner.
Saxagliptin inhibits DPP-4, increasing incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
25 mg orally once daily.
Each tablet contains saxagliptin 5 mg and metformin hydrochloride 500 mg or 1000 mg. The recommended starting dose is 5 mg saxagliptin and 500 mg metformin hydrochloride orally twice daily; titrate gradually based on efficacy and tolerability. Maximum daily dose: saxagliptin 5 mg, metformin hydrochloride 2000 mg.
None Documented
None Documented
Terminal elimination half-life: 12.4–26.1 hours (mean ~21 hours); supports once-daily dosing
Saxagliptin: 2.5 hours (parent), 3.1 hours (active metabolite). Metformin: 6.2 hours (plasma), prolonged in renal impairment.
Renal: 87% (75% as unchanged drug, 12% as inactive metabolites); Fecal: <1%
Saxagliptin: 75% renal (24% unchanged, 51% as metabolite), 22% fecal. Metformin: 90% renal (unchanged).
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor